Voceryq study: seven of 26 adults in the efficacy group met the endpoint of no surgical intervention in the 12 months after treatment. Nineteen did not meet that endpoint. The study enrolled 32 adults overall and had no randomized control group.
A year without another surgery: seven of 26 adults in the efficacy group met that endpoint. The trial enrolled 32 adults overall. Original SpecStocks graphic from FDA labeling; no source artwork reproduced. [3]
Study data and limits
Voceryq RRP-001 study; adult efficacy group
Outcome at 12 months after treatmentPatients
Met no-surgery endpoint7
Did not meet endpoint19
Total efficacy group26

19 = 26 - 7. 7 / 26 = 26.92%, rounded to 27% in the label; 95% confidence interval 12% to 48%. Each dot represents one patient. Of 32 treated adults, the efficacy group comprised 26 with at least three surgeries in the preceding year. The open-label, single-arm study had no randomized comparison group. This is an observed study outcome, not a cure rate or a forecast for every patient. Source: FDA prescribing information, October 2026, section 14. Factual data redrawn by SpecStocks.

INOVIO has won its first U.S. drug approval with a treatment aimed at sparing adults repeated airway surgery. On October 30, the Food and Drug Administration granted accelerated approval to Voceryq for a rare disease that makes growths return inside the respiratory tract. [1] [2]

For INOVIO (Nasdaq: INO), the decision opens a path from drug development to selling a medicine. The company expects orders and shipments in about 60 days, followed by a full commercial launch in early 2027. [1]

Giving the immune system a different job

The disease, recurrent respiratory papillomatosis, is caused by human papillomavirus. Its wart-like growths can obstruct airways. Removing them can become a recurring task because surgery does not necessarily stop them returning. [2]

Voceryq uses small circular pieces of DNA to help the body's cells produce targets for an immune response against the virus. An accompanying device, CELLECTRA, uses brief electrical pulses to help deliver the medicine into cells. [1] [2]

The approved regimen still begins with surgery to remove visible growths. It then involves four doses, three weeks apart, delivered by a healthcare professional trained to use the device. The medicine therefore adds a treatment course after that initial operation. [3]

“For patients, that could mean fewer surgeries, fewer disruptions, and more time living their lives on their own terms.”

Karim Mikhail, director of the FDA's Center for Biologics Evaluation and Research, October 30, 2026 [2]

A meaningful result, with a small evidence base

The study treated 32 adults. Its efficacy analysis focused on 26 who had needed at least three operations during the previous year. Seven of those 26 needed no surgical intervention in the 12 months after treatment, meeting the study's main endpoint. [3]

That is 27%, with considerable uncertainty in such a small group. The trial had no randomized control group. Reported side effects included injection-site reactions, headache and fatigue, among others. [3]

Voceryq also enters a market with another approved immunotherapy: the FDA cleared Papzimeos for adults with the same disease in August 2025. Friday's decision gives patients another option; it does not establish that INOVIO's medicine is superior. [7]

The launch needs people, devices and money

INOVIO has engaged Syneos Health to help recruit and deploy medical and commercial teams. Selling a medicine used with a dedicated device requires clinics to be ready as well as cartridges to be available. Its shipment and launch dates remain company expectations. [1]

The financial starting point is modest. INOVIO reported $36.7 million of cash and short-term investments at June 30, before roughly $18.3 million of net proceeds from July financing. In August, it projected funding into late first-quarter 2027. Those are dated figures and a company forecast, not today's cash balance. [5]

The market connection Approval creates a product to sell, while launch spending and further trials still need funding. Additional share sales could dilute existing INOVIO owners. [6]

The FDA requires a confirmatory study, with a draft plan due December 30, 2026. Its approval letter warns that failure to verify clinical benefit, or to pursue the study diligently, can lead to withdrawal. [4]

INOVIO plans to discuss commercialization on November 2. The next chapter is getting the treatment into clinics and building sales while continuing to establish its benefit. [1]